Compare LAB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | ABEO |
|---|---|---|
| Founded | 1999 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.5M | 307.5M |
| IPO Year | 2008 | 2005 |
| Metric | LAB | ABEO |
|---|---|---|
| Price | $0.81 | $5.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.35 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 3.5M | 889.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.54 | ★ 165.16 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $101,937,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | $2.63 | $145.42 |
| P/E Ratio | $2.52 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $0.79 | $4.00 |
| 52 Week High | $1.72 | $7.54 |
| Indicator | LAB | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 52.77 |
| Support Level | N/A | $5.24 |
| Resistance Level | $1.02 | $5.64 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 6.86 | 54.61 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.